31 July 2020 : Database Analysis
Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma
Dehua Zhang1ACD, Muchun Zhang2B, Qifu Zhang3DF, Zhiyi Zhao3BCF, Yong Nie1ADE*DOI: 10.12659/MSM.924543
Med Sci Monit 2020; 26:e924543
Table 1 Baseline information of patients diagnosed with PRAD.
| Variables | Total patients (N=500) |
|---|---|
| Mean±SD | 61.01±6.82 |
| Median (range) | 61 (41–78) |
| Female | 0 (0.00%) |
| Male | 500 (100.00%) |
| T2a | 13 (2.60%) |
| T2b | 10 (2.00%) |
| T2c | 165 (33.00%) |
| T3a | 159 (31.80%) |
| T3b | 136 (27.20%) |
| T4 | 10 (2.00%) |
| Unknown | 7 (1.40%) |
| N0 | 348 (69.60%) |
| N1 | 79 (15.80%) |
| Unknown | 73 (14.60%) |
| Adenocarcinoma, NOS | 487 (97.40%) |
| Adenocarcinoma with mixed subtypes | 3 (0.60%) |
| Infiltrating duct carcinoma, NOS | 9 (1.80%) |
| Mucinous adenocarcinoma | 1 (0.20%) |
| 6 | 45 (9.00%) |
| 7 | 250 (50.00%) |
| 8 | 64 (12.80%) |
| 9 | 137 (27.40%) |
| 10 | 4 (0.80%) |
| Mean±SD | 1.86±3.39 |
| Median (range) | 0.10 (0.01–323.00) |
| Unknown | 84 (16.80%) |
| PRAD – prostate adenocarcinoma; SD – standard deviation; NOS – not otherwise specified; PSA – prostate-specific antigen. | |